Archives

  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-11
  • 2018-10
  • 2018-07

    • SM-102 in Lipid Nanoparticles: Mechanism, Evidence, and m...

    2025-11-04

    SM-102 in Lipid Nanoparticles: Mechanism, Evidence, and mRNA Vaccine Applications

    Executive Summary:
    SM-102 is a synthetic amino cationic lipid optimized for mRNA delivery via lipid nanoparticles (LNPs), showing efficient mRNA encapsulation and cellular uptake at concentrations of 100–300 μM in vitro (ApexBio). It is a core excipient in advanced mRNA vaccine platforms, notably enabling delivery in preclinical and clinical systems (Wang et al., 2022). Machine learning models have validated the structure-performance relationship for ionizable lipids like SM-102, confirming its efficacy but also revealing benchmark differences versus alternatives (e.g., MC3 lipid outperforms SM-102 in some settings). SM-102’s mechanism centers on facilitating endosomal escape and efficient cytosolic release of mRNA. Practical application requires precise formulation parameters and awareness of system-specific limitations.

    Biological Rationale

    Lipid nanoparticles (LNPs) are the leading non-viral vectors for mRNA delivery. mRNA-based therapeutics and vaccines require protection from extracellular RNases, efficient cellular uptake, and cytosolic release. Ionizable cationic lipids like SM-102 are designed to bind and condense mRNA molecules, form stable nanoparticles, and disrupt endosomal membranes under acidic conditions. SM-102 features a tertiary amine headgroup that becomes protonated at low pH, triggering endosomal escape. Its hydrophobic tails facilitate self-assembly with helper lipids, cholesterol, and PEG-lipids. SM-102 is critical to the architecture of LNPs used in mRNA-1273 (Moderna) and other research-stage vaccines (Wang et al., 2022). Concentrations between 100 and 300 μM are commonly used to modulate erg-mediated K+ currents in vitro, suggesting additional regulatory effects on cellular signaling (ApexBio).

    Mechanism of Action of SM-102

    SM-102 acts as an ionizable cationic lipid within LNPs. At physiological pH (~7.4), SM-102 is mostly neutral, reducing toxicity and increasing biocompatibility. Under acidic conditions (e.g., 90%) and robust delivery to mammalian cells (Wang et al., 2022).

    • SM-102 forms stable LNPs in combination with cholesterol, DSPC, and PEG-lipids.
    • mRNA is electrostatically complexed and shielded from degradation until release.
    • Endosomal acidification triggers SM-102 protonation and membrane fusion.
    • LNPs with SM-102 show particle sizes typically 80–100 nm (dynamic light scattering at 25°C, pH 7.4).

    Evidence & Benchmarks

    • SM-102 is a validated ionizable lipid for LNP-based mRNA delivery, with high encapsulation efficiency and in vivo transfection rates (Wang et al., 2022, DOI).
    • Machine learning (LightGBM) models ranked SM-102 below MC3 in mouse IgG titer outputs, indicating but not excluding efficacy for vaccine applications (Wang et al., 2022, DOI).
    • LNPs formulated with SM-102 at N/P ratios (nitrogen/phosphate) of 6:1 are standard in murine models (Wang et al., 2022, DOI).
    • Studies confirm SM-102’s ability to regulate the erg-mediated K+ current in GH cells at 100–300 μM, linking to potential signaling pathway modulation (ApexBio).
    • Comparative articles (e.g., SM-102 in Lipid Nanoparticles: Predictive Formulation) show that this article uniquely integrates mechanistic benchmarking and application limits, extending previous predictive or translational analyses.

    Applications, Limits & Misconceptions

    SM-102 is used in the formulation of mRNA LNPs for preclinical and clinical research. Its prominent role in vaccine development has been demonstrated in SARS-CoV-2 mRNA vaccines. SM-102 is also applied in broader mRNA therapeutic pipelines (e.g., protein replacement, immunotherapy). However, machine learning and experimental benchmarks show that SM-102, while robust, may be less potent than MC3 in certain animal models or endpoints (Wang et al., 2022).

    • SM-102 does not support mRNA delivery in the absence of helper lipids or cholesterol.
    • Performance is formulation- and target-dependent; direct translation between animal models and humans is not guaranteed.
    • SM-102 is not suitable for DNA delivery or gene editing without further optimization.
    • For regulatory and safety endpoints, SM-102 is for research use only, not for human consumption.

    Common Pitfalls or Misconceptions

    • SM-102 alone cannot form functional LNPs; it requires co-formulation with helper lipids, cholesterol, and PEG-lipids.
    • High encapsulation efficiency does not guarantee in vivo efficacy; immunogenicity and biodistribution are also critical.
    • SM-102 is not interchangeable with all other ionizable lipids; structure-activity relationships matter.
    • Not all published LNP protocols using SM-102 are directly transferable across mRNA sequences or payloads.
    • SM-102’s use is restricted to research; it is not approved for therapeutic use in humans.

    Workflow Integration & Parameters

    For researchers, SM-102 is available as a standardized formulation component (see the C1042 kit). Key parameters include:

    • Concentration: Typical working range is 100–300 μM for in vitro studies.
    • Formulation: Combine with cholesterol, DSPC, and PEG-lipids at molar ratios optimized for stability and encapsulation.
    • N/P Ratio: 6:1 (nitrogen:phosphate) is standard for murine models.
    • Particle size and polydispersity: Validate by dynamic light scattering (DLS); aim for 80–100 nm diameter, PDI < 0.2.
    • Storage: Store SM-102 at –20°C, protected from light and moisture.

    For advanced mechanistic insight, see SM-102 in Lipid Nanoparticles: Mechanistic Insights, which focuses on biophysical properties, while the current article extends to workflow integration and practical limitations.

    Conclusion & Outlook

    SM-102 is a validated, research-grade ionizable lipid for LNP-based mRNA delivery, supporting breakthroughs in vaccine and gene therapy development. Its efficient encapsulation, endosomal escape mechanism, and integration within predictive modeling pipelines make it a reference point for ongoing LNP innovation. Future research will refine SM-102’s role relative to next-generation ionizable lipids, optimize its use across mRNA payloads, and address translational challenges from bench to clinic. For a strategic outlook on SM-102-enabled advances, see SM-102 Lipid Nanoparticles: Mechanistic Mastery and Strategy, which synthesizes experimental and strategic perspectives, whereas this article provides a granular, evidence-based dossier.